United Kingdom· GB-APID-4496611000001107
Cosmegen Lyovac 500microgram powder for solution for injection vials
A dactinomycin product containing dactinomycin, registered in United Kingdom by Recordati Rare Diseases UK Ltd. The same ATC class is registered in 7 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Dactinomycin is registered in 7 of 19 countries.
Countries holding a registration under ATC L01DA01 (dactinomycin), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 4 of them publish a price we can compare per daily dose
Dactinomycin · ATC L01DA01
7 / 19 countries
- Canada
- Finlandprice
- Franceprice
- Germany
- Norwayprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Dactinomycin
- Manufacturer
- Recordati Rare Diseases UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01DA01
- ATC class
- Dactinomycin
- Defined daily dose
- 0.32 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin3663502000410
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
163 interactions on record for dactinomycin.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dactinomycin · interactions on record
163 records
- 30 severe
- 83 moderate
- 15 minor
- 35 info
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Dactinomycin in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayLyovac-CosmegenOrphan Europe
- United StatesdactinomycinXGen Pharmaceuticals DJB, Inc.
- GermanyLyovac-CosmegenRecordati Rare Diseases
- FinlandCosmegenLundbeck Pharmaceuticals Ireland Limited
- CanadaCOSMEGENRECORDATI RARE DISEASES CANADA INC
- JapanアクチノマイシンＤノーベルファーマ
- FranceCOSMEGEN 0,5 mg, poudre pour solution injectableRECORDATI RARE DISEASES
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Germany · Lyovac-Cosmegen
- France · Cosmegen
- Italy · Cosmegen
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8a5d96f2-f7df-45bb-9313-5b110c3243e4 GET /v1/drugs/8a5d96f2-f7df-45bb-9313-5b110c3243e4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "4496611000001107",
"desc": "Cosmegen Lyovac 500microgram powder for solution for injection vials (Recordati Rare Diseases UK Ltd)",
"form": "Powder for solution for injection",
"vpid": "41785311000001109",
"source": "dmd",
"vtm_id": "775436009",
"strength": "500 microgram",
"substance": "Dactinomycin",
"ingredient": "Dactinomycin",
"supplier_code": "3371801000001103"
}See everything about dactinomycin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.